CEO: Win or lose on Ampyra patents, Acorda reps are safe with Parkinson's prospect

The threat of generics often means layoffs, and in the case of Acorda’s Ampyra, that’s been true. But even if the company loses its upcoming appeal on the multiple sclerosis drug’s patents, its sales force won’t have to worry.